November 10, 2016 / 12:42 PM / 9 months ago

BRIEF-Theratechnologies gives results of late stage HIV study

Nov 10 (Reuters) - Theratechnologies Inc

* Theratechnologies inc says ibalizumab maintains significant reduction of viral load in patients with multi-drug resistant hiv-1 over 24 weeks

* Theratechnologies inc says results from study support regulatory submission of bla to us fda

* Theratechnologies inc - phase iii trial confirms safety and efficacy results of ibalizumab observed in previously completed phase iib study

* Theratechnologies announces results from the last pivotal phase iii trial of hiv long acting biologic (lab) investigational antiretroviral ibalizumab. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below